Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Walmart Rolls Out Budget Insulin As Low-Income Diabetics Struggle To Afford Drug

Courtesy of ZeroHedge View original post here.

Walmart on Tuesday announced that it will begin selling a far less expensive, private-label version of insulin which could help low-income diabetics afford their medication.

Starting this week, the retailer will begin selling their exclusive insulin, ReliOn NovoLog, according to CNBC, with availability at its membership-based Sam's Club in mid-July. The cost will be $73 per vial, or around $86 for a package of prefilled insulin pens. Branded competitors are selling the same formulation for as much as $101 per vial / $251 per pack of insulin pens.

More than 34 million people in the U.S. — or nearly 11% of the population — have diabetes, and about 1.5 million Americans are diagnosed every year, according to the American Diabetes Association. That percentage is about 14% among Walmart shoppers, said Warren Moore, Walmart's vice president of health and wellness, on a call.

As the number of people with diabetes climbs, the cost of the 100-year-old drug has soared rather than fallen and drawn scrutiny from lawmakers. The annual cost of insulin for people with Type 1 diabetes in the U.S. nearly doubled from $2,900 in 2012 to $5,700 in 2016, according to the most recent data available from the Health Care Cost Institute. -CNBC

According to the American Diabetes Association, 25% of diabetics have  turned to rationing doses during the pandemic, while the disease has skyrocketed among low-income individuals over the last decade compared to those classified as middle income or near-poor.

Walmart EVP of health and wellness, Dr. Cheryl Pegus, said the company's version of the drug – made by Novo Nordisk, will expand access to care.

"This price point, we hope, will improve and hopefully revolutionize the accessibility and affordability of insulin," said Pegus during a call with reporters. "We know that many people with diabetes struggle to manage this chronic condition because of its financial burden."


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!